Bottom line
TNA vs CURE: the short answer
TNA (Direxion Daily Small Cap Bull 3X ETF) and CURE (Direxion Daily Healthcare Bull 3X ETF) are both etfs.
But CURE is far broader, holding 67 positions to 12 for TNA, so beyond the top names it adds exposure TNA doesn't have.
CURE is cheaper at 0.94% vs 1.05% — a difference of $11 a year per $10,000 invested.
Over five years, CURE returned +8.6% a year vs −6.5% for TNA.
Updated Nov 19, 2026
TNA vs CURE side by side
| TNA | CURE | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 1.05% | 0.94% |
| Annual cost per $10k | $105 | $94 |
| 10-yr cost on $10k (prospectus) | $1,304 | $1,155 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +9.8% | +22.9% |
| 5-yr return (annualized) | −6.5% | +8.6% |
| 10-yr return (annualized) | +4.1% | +13.6% |
| Best quarter | +116.8% | +46.9% |
| Worst quarter | −76.9% | −45.8% |
| Net assets (fund) | $1.3B | $171.7M |
| Number of holdings | 12 | 67 |
| Portfolio turnover | 188% | 1% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | TNA | CURE | Difference |
|---|---|---|---|
| 2025 | +9.8% | +22.9% | −13.1% |
| 2024 | +7.3% | −8.5% | +15.8% |
| 2023 | +26.0% | −9.8% | +35.7% |
| 2022 | −62.4% | −20.4% | −42.1% |
| 2021 | +28.1% | +87.4% | −59.3% |
| 2020 | −8.2% | +5.1% | −13.3% |
| 2019 | +71.8% | +55.9% | +16.0% |
| 2018 | −39.7% | +2.9% | −42.7% |
| 2017 | +39.6% | +69.3% | −29.7% |
| 2016 | +58.0% | −17.4% | +75.4% |
Source: Fund prospectus bar charts
Holdings overlap
10 of TNA's top 12 holdings also appear in CURE's top 25.
| Holding | TNA | CURE |
|---|---|---|
| Dreyfus | 16.60% | 18.79% |
| N/a | 6.49% | 1.12% |
| Goldman Sachs Liq Es Fd A | 6.27% | 8.19% |
| Goldman Financial | 4.72% | 7.51% |
| N/a | 4.64% | 1.12% |
| N/a | 4.63% | 1.12% |
| N/a | 4.18% | 1.12% |
| N/a | 1.86% | 1.12% |
| N/a | 1.39% | 1.12% |
| N/a | 0.89% | 1.12% |
Source: SEC Form N-PORT
TNA top 10
- Ishares MSCI Eafe Small-cap — 69.70%
- Dreyfus — 16.60%
- N/a — 6.49%
- Goldman Sachs Liq Es Fd A — 6.27%
- Goldman Financial — 4.72%
- N/a — 4.64%
- N/a — 4.63%
- N/a — 4.18%
- N/a — 1.86%
- Dreyfus — 1.59%
CURE top 10
- Dreyfus — 18.79%
- Eli Lilly & Company — 10.41%
- N/a — 8.28%
- Goldman Sachs Liq Es Fd A — 8.19%
- Goldman Financial — 7.51%
- Johnson & Johnson — 7.07%
- Abbvie Inc — 5.08%
- Unitedhealth Group Inc — 4.31%
- Merck & Company Inc — 3.68%
- N/a — 3.34%
FAQ
What is the difference between TNA and CURE?
Which is cheaper, TNA or CURE?
Should I own both TNA and CURE?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.